Terms ending in 2030
Every in-force patent on Phio Pharmaceuticals Corp.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,167,471 | Inhibition of PCSK9 Through Rnai In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 9,745,574 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 10,479,992 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence | |
| US 11,667,915 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence | |
| US 8,796,443 | Reduced Size Self-Delivering Rnai Compounds In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence | |
| US 9,074,211 | Inhibition of MAP4K4 Through Rnai In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.